Re: ImmunoGen and Merck Establish Collaboration
Q & A:
Michelle Gilson
Hi, this is Michelle. I was just wondering if or when we might see any data from FORWARD I since its open label? And then we also were just wondering maybe what you are seeing pre-clinically with the PD1 and mirvetuximab? And then maybe when you plan to initiate studies with that combo?
Dan Junius
Michelle, on the second question regarding preclinical data, I think you specifically asked about a checkpoint inhibitor plus mirvetuximab. That’s an area that we are very interested in. We have discussed some preclinical work that we have done in the B-cell area. And you heard me reference the study that Roche announced that would include looking at Kadcyla, in combination with their PD-L1. We haven’t disclosed any preclinical work there. I think the larger point is that given that the preclinical work that’s been done looking at maytansine as a class in combination with checkpoint inhibitors carries potential across both our and our partner product lines, so something that we want to assess. I think there is the opportunity to assess that clinically without doing extensive preclinical work once safety has been proven with a maytansine-based ADC. So, I think that as you are seeing with others, there is the opportunity to move directly into the clinic to look at some of those without necessarily even having a lot of preclinical work done. So, it’s something that we are quite interested in both for our own pipeline as well as our partner pipelines.